ResMed's Dominance in CPAP Market Expands with Wearables and Digital Tools.

ResMed's share price has grown 22.2% over three years and 36.7% over five years, driven by the expansion of sleep apnea treatment and respiratory care. The company's recurring revenue model in masks, supplies, and software has benefited from the adoption of wearables, fresh FDA approvals, and the Philips CPAP recall. ResMed's digital ecosystem is playing a larger role in patient adherence and provider decision-making, supporting its core business of supplying CPAP devices, masks, and cloud-based software.